Diamyd Medical AB (publ) (DMYD-B.ST) Research

Diamyd Medical AB (publ), a Swedish company founded in Stockholm in 1984, specializes in developing innovative treatments for autoimmune diabetes. Formerly known as Diamyd Therapeutics AB until its name change in April 2013, the company is advancing two key therapeutic candidates. Its flagship product, Diamyd, is an antigen-specific immunotherapy vaccine for diabetes currently undergoing Phase IIb clinical studies for both type 1 diabetes and latent autoimmune diabetes. Additionally, Remygen, an oral drug candidate with regenerative and immunomodulatory properties, is progressing through Phase I/II clinical trials for the treatment of autoimmune and type 2 diabetes.

Market snapshot

Symbol
DMYD-B.ST
Price
$1.09
Day change
-1.81%
Market cap
$145.8M
P/E ratio
-0.70x
52-week range
0.896-17.88
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • BICO Group AB (publ) (BICO.ST)
  • BioInvent International AB (publ) (BINV.ST)
  • Cantargia AB (publ) (CANTA.ST)
  • Egetis Therapeutics AB (publ) (EGTX.ST)
  • Genovis AB (publ.) (GENO.ST)
  • Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
  • Oncopeptides AB (publ) (ONCO.ST)
  • OssDsign AB (publ) (OSSD.ST)

Open Diamyd Medical AB (publ) (DMYD-B.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.